Abstract
Hepatitis E virus (HEV) infection can cause hepatic and extra-hepatic manifestations. Treatment of HEV infection has been thoroughly studied in solid-organ-transplant patients who have developed a chronic HEV infection. In this review, we report on our current knowledge regarding treatment of HEV infection.
Highlights
It is known that hepatitis E virus infections with genotypes 1 and 2 (HEV-1 and -2) are responsible for self-limiting hepatitis, and for fulminant hepatitis in patients with underlying chronic liver disease and in pregnant women [1]
Thereafter, several case series have reported on chronic Hepatitis E virus (HEV) infection in patients that have undergone stem-cell transplantation [3], hematology patients that have received chemotherapy [4], rheumatology patients that have received monoclonal antibodies [5], and patients infected by human immunodeficiency virus (HIV) that have low CD4 counts [6]
The impact of chronic HEV infection has been mainly evaluated in solid-organ transplant (SOT) patients
Summary
It is known that hepatitis E virus infections with genotypes 1 and 2 (HEV-1 and -2) are responsible for self-limiting hepatitis, and for fulminant hepatitis in patients with underlying chronic liver disease and in pregnant women [1]. No cases of chronic hepatitis have been described in these settings [1]. HEV genotypes 3 and 4 (HEV-3 and -4) mainly induce self-limiting hepatitis, fulminant hepatitis in patients with chronic liver disease, but not in pregnant women [1]. The first cases of chronic hepatitis were described in patients with a solid-organ transplant (SOT) [2]. The impact of chronic HEV infection has been mainly evaluated in SOT patients. Treatments for HEV infection were initially evaluated in SOT patients. We describe our current knowledge regarding treatment of HEV infection within different settings
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have